For example, in Nguyen et al., multiple PDX were developed, reflecting prostate cancer features such as AR amplification, PTEN deletion, TP53 deletion/mutation, RB1 loss, TMPRSS2-ERG rearrangements, SPOP mutation, MSH2/MSH6 genomic aberrations, and BRCA2 loss [26]. Here, TP53 is linked to prostate carcinoma.